1
$\begingroup$

Couldn't VEGF help with ligament recovery? I looked it up and found some studies in rats, but nothing on people. VEGF inhibitors tend to be used more often then VEGF.

Why isn't VEGF being used in people? What would generally happen if VEGF was injected into a person?

EDIT Here is the one study that examined injection VEGF in rats for increasing skin viability.

Also I am not really asking about the effect of VEGF on ligaments. I just figured that because there is little vasculature surrounding ligaments (and cartilage), VEGF could in theory improve recovery of such injuries. The bigger question is why aren't people ever injected with VEGF?

$\endgroup$
2
$\begingroup$

VEGF is a family of growth factors that promote angiogenesis and vasculogenesis.

Vascularization is a key step in the progression of cancer, so the VEGF family has often been a target for suppression: preventing vascularization of tumors can stop their further growth.

That said, your premise that VEGF hasn't been tried clinically is false: there have been several clinical trials of VEGF (and no doubt more that I didn't find).

Hedman, et al 2003 used catheter-based VEGF gene transfer at the time of angioplasty/stenting, though they found it did not prevent restenosis they did see increased perfusion (it seems to me that further research didn't show sufficient effects on long-term outcomes). Ripa, et al 2006 used VEGF gene transfer as part of a treatment for ischemic heart disease. It seemed like the treatment was safe, but the efficacy was limited. Ropper, et al. 2009 attempted VEGF gene transfer for the treatment of diabetic polyneuropathy. They found some improvement of pain, and report a fairly high rate of adverse events but their control group also experienced adverse events.

It seems like a similar VEGF plasmid is available in Russia as Neovasculgen for use in limb ischemia; the company developing the drug is in the process of beginning to get approval elsewhere.

VEGF as a topical application has been studied under the name telbermin, for example Hanft, et al 2008.

There may be others, but I stopped my search there. https://clinicaltrials.gov/ is a good place to start looking for what research has been done in humans if you have trouble finding journal articles at first.


Hanft, J. R., Pollak, R. A., Barbul, A., Gils, C. V., Kwon, P. S., Gray, S. M., ... & Breen, T. J. (2008). Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of wound care, 17(1), 30-37.

Hedman, M., Hartikainen, J., Syvänne, M., Stjernvall, J., Hedman, A., Kivelä, A., ... & Närvänen, O. (2003). Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation, 107(21), 2677-2683.

Ripa, R. S., Wang, Y., Jørgensen, E., Johnsen, H. E., Hesse, B., & Kastrup, J. (2006). Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. European heart journal, 27(15), 1785-1792.

Ropper, A. H., Gorson, K. C., Gooch, C. L., Weinberg, D. H., Pieczek, A., Ware, J. H., ... & Kirchmair, R. (2009). Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double‐blinded trial. Annals of neurology, 65(4), 386-393.

Simovic, D., Isner, J. M., Ropper, A. H., Pieczek, A., & Weinberg, D. H. (2001). Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia. Archives of neurology, 58(5), 761-768.

$\endgroup$
  • $\begingroup$ These are interesting articles. However, they all appear to be utilizing gene transfer therapy methods rather than hormone therapy. Are you sure you found studies that utilized VEGF and not VEGF plasmids? $\endgroup$ – J Houseman Jul 5 at 21:42
  • $\begingroup$ @JHouseman That seems to be the typical approach. The Hanft paper is VEGF itself rather than plasmid, you can find more searching telbermin. As you'll note in the cardiac work, part of the point is to have VEGF present where needed, such as the site of angioplasty, and also the desire to have VEGF present over a long time period, hence the use of plasmids. It may be easier to inject VEGF directly in an animal study where the animal is always in the lab, but not really feasible for human use. $\endgroup$ – Bryan Krause Jul 5 at 22:05

Your Answer

By clicking “Post Your Answer”, you agree to our terms of service, privacy policy and cookie policy

Not the answer you're looking for? Browse other questions tagged or ask your own question.